🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China as lead sponsor. Synced 26 Sep 2026
6Current trials
6Recruiting now
1Drug in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China is the lead sponsor of 6 current clinical trials in our China register. 6 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are JY231. The most-studied condition is ITP - Immune Thrombocytopenia.

ClinicalTrials.gov trials by status

  • Recruiting6100%

Trials by phase

  • Phase 1/2233%
  • Phase EARLY_PHASE1233%
  • Not applicable233%
01

Clinical trials sponsored by 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
NCT06352281 · ClinicalTrials.gov ↗ · ITP - Immune Thrombocytopenia
Phase 1/2 Recruiting 2024-02 China
Safety and Preliminary Efficacy of Anti-CDH17 CAR-T Cell Therapy in Patients with CDH17-positive Advanced Solid Tumors
NCT06820424 · ClinicalTrials.gov ↗ · CDH17-positive Advanced Solid Tumors
Phase EARLY_PHASE1 Recruiting 2025-03 China
JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06514768 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia (B-ALL)
Drug: JY231
Phase EARLY_PHASE1 Recruiting 2024-06 China
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
NCT06515262 · ClinicalTrials.gov ↗ · Relapsed/Refractory Multiple Myeloma
Not applicable Recruiting 2024-07 China
JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
NCT06675422 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE)
Phase 1/2 Recruiting 2024-10 China
JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies
NCT07065279 · ClinicalTrials.gov ↗ · B-cell Malignancies
Drug: JY231
Not applicable Recruiting 2025-07 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China trials

6 conditions
ITP - Immune Thrombocytopenia1CDH17-positive Advanced Solid Tumors1B-cell Acute Lymphoblastic Leukemia (B-ALL)1Relapsed/Refractory Multiple Myeloma1Systemic Lupus Erythematosus (SLE)1B-cell Malignancies1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China66

A trial with sites in more than one country appears in each of those registers.

05

Questions about 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China trials

How many clinical trials does 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China sponsor?

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China is the lead sponsor of 6 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China trials recruiting?

Yes. 6 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China testing?

Its current trials name 1 drug or biological as interventions. The most frequent are JY231 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.